Open AccessSTANDARDS OF MEDICAL CARE “INVASIVE CANDIDIASIS IN NEWBORNS”
Author(s) -
D. Dobryanskyy,
О. В. Гуленко,
T. Znamenska,
О. В. Воробйова
Publication year - 2021
Publication title -
neonatologìâ, hìrurgìâ ta perinatalʹna medicina
Language(s) - English
Resource type - Journals
eISSN - 2413-4260
pISSN - 2226-1230
DOI - 10.24061/2413-4260.xi.4.42.2021.12
Subject(s) - micafungin , invasive candidiasis , fluconazole , medicine , incidence (geometry) , intensive care medicine , neonatal intensive care unit , low birth weight , amphotericin b , pediatrics , candida infections , antifungal , systemic candidiasis , dermatology , pregnancy , corpus albicans , biology , physics , optics , genetics
Candida infection (candidiasis) is an important clinical problem in newborns who need treatment in modern intensive care units. Organ and/or systemic infections caused by these fungi are called invasive candidiasis (IC). Newborns are especially vulnerable to IC, and their incidence is 3-5 times higher than the corresponding rates in children or adults. Invasive fungal infections caused by Candida are the third most common late-onset infection in infants born with a birth weight <1500 g. IC in newborns is associated with approximately 20% mortality, and about half of survivors have serious long- term neurological damage. In recent years, new data have been obtained on the diagnosis, prevention and treatment of IC in newborns, which has determined a change in treatment recommendations. Accordingly, the need arose to ensure the compliance of our clinical practice with modern evidence-based approaches. Early diagnosis of candidiasis and prompt treatment with effective antifungal agents such as fluconazole, amphotericin B, and micafungin, when indicated, are critical to improving outcomes.